**Supplemental Table 1. Fibrocyte value change over time.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | n | Fibrocyte | SD | p-value |
| Baseline | 51 | 6.64 | 5.77 |  |
| 6 month | 51 | 5.99 | 5.16 |  |
| difference | 51 | 0.65 | 0.75 | 0.38 |

*Paired t-test indicated no significant difference between baseline and 6 month values. Repeated measures ANOVA with Greenhouse-Geisser effect correction F (1,48) = 1.48; p=0.18.*

**Supplemental Table 2. Demographic representation in PROFILE**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Unsampled | Sampled |  |
| N | 462 | 119 | p-value |
| Age (IQR) | 72 (66-77) | 73 (67-78) | 0.821 |
| Male | 78.14% | 74.79% | 0.436 |
| Smoker | 67.61% | 75.63% | 0.091 |
| FVC %pred (SD) | 76.7 (19.6) | 82.7 (20.0) | 0.004 |
| DLCO %pred (SD) | 42.9 (15.7) | 48.7 (16.3) | 0.001 |

*Non-normally distributed data presented as median and interquartile range (IQR) and assessed by Mann-Whitney, normally distributed data presented as mean and standard deviation (SD) and assessed by unpaired t-test. Numbers in groups assessed by chi-squared.*

**Supplemental Table 3. Risk of overall mortality at optimal threshold of circulating fibrocytes in IPF: pooled analysis.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | n | died | HR | 95%CI | p-value | HR\* | 95%CI\* | p-value\* |
| Moeller | 60 | 16 | **3.93** | **(1.27-12.21)** | **0.018** | 2.33 | (0.74-7.35) | 0.148 |
| PROFILE | 102 | 38 | **2.38** | **(1.09-5.21)** | **0.030** | **2.80** | **(1.21-6.49)** | **0.017** |
| Overall | 162 | 54 | **2.70** | **(1.65-4.42)** | **<0.001** | **2.50** | **(2.37-2.64)** | **<0.001** |

*\*Hazard ratio (HR) for 2.22% threshold of circulating fibrocyte level adjusted for gender, age, percent predicted FVC and steroid immunosuppression in multilevel mixed-effects model with random intercept for Study. Significant estimates in bold.*

**Supplemental Figure 1. Area under ROC of fibrocyte for overall mortality**



*Area under Recevier Operator Characteristic curve for % circulating fibrocytes as a continuous variable (AUROC 0.59 95%CI 0.48;0.71) and dichotomised at thresholds of 5.00% (AUROC 0.57 95%CI 0.56;0.67) and 2.22% (AUROC 0.61 95%CI 0.52;0.70). Sensitivity and specificity at 2.22% threshold 0.79 and 0.42, respectively.*